Transcriptional networks controlling skeletal development

Current Opinion in Genetics and Development

Volumn 19, Issue 5, 2009, Pages 437-443

  Hartmann, Christine ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CMAF; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX8; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; BONE REMODELING; CARTILAGE CELL; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL SIZE; CELL STIMULATION; CELL TYPE; CHONDROGENESIS; DOWN REGULATION; GENE EXPRESSION REGULATION; GROWTH REGULATION; HUMAN; HYPERTROPHY; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; STEM CELL; TRANSCRIPTION REGULATION;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; CELL DIFFERENTIATION; CHONDROGENESIS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE REGULATORY NETWORKS; HUMANS; MODELS, BIOLOGICAL; OSTEOBLASTS; TRANSCRIPTION, GENETIC;

VERTEBRATA;

EID: 71849093619     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2009.09.001     Document Type: Review

References (60)

1. Akiyama H. Control of chondrogenesis by the transcription factor Sox9. Mod Rheumatol 18 (2008) 213-219. This review gives an excellent overview of the complex actions of the transcription factor Sox9 and lists the relevant original publications.
2. Zhou G., Zheng Q., Engin F., Munivez E., Chen Y., Sebald E., Krakow D., and Lee B. Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci U S A 103 (2006) 19004-19009
3. Yamashita S., Andoh M., Ueno-Kudoh H., Sato T., Miyaki S., and Asahara H. Sox9 directly promotes Bapx1 gene expression to repress Runx2 in chondrocytes. Exp Cell Res 315 (2009) 2231-2240. In this study Bapx1/Nkx3.2 was identified as a direct target and by using shRNA mediated knock-down of Bapx1 in cultured chondrocytes the authors showed an increase in Runx2 expression. This nicely provides a mechanistic link for previous studies [2,4] and the study by Provot et al. [58]
4. Lengner C.J., Hassan M.Q., Serra R.W., Lepper C., van Wijnen A.J., Stein J.L., Lian J.B., and Stein G.S. Nkx3.2-mediated repression of Runx2 promotes chondrogenic differentiation. J Biol Chem 280 (2005) 15872-15879
5. Takahashi K., Nuckolls G.H., Takahashi I., Nonaka K., Nagata M., Ikura T., Slavkin H.C., and Shum L. Msx2 is a repressor of chondrogenic differentiation in migratory cranial neural crest cells. Dev Dyn 222 (2001) 252-262
6. Peters H., Wilm B., Sakai N., Imai K., Maas R., and Balling R. Pax1 and Pax9 synergistically regulate vertebral column development. Development 126 (1999) 5399-5408
7. Herbrand H., Pabst O., Hill R., and Arnold H.H. Transcription factors Nkx3.1 and Nkx3.2 (Bapx1) play an overlapping role in sclerotomal development of the mouse. Mech Dev 117 (2002) 217-224
8. Rodrigo I., Hill R.E., Balling R., Munsterberg A., and Imai K. Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome. Development 130 (2003) 473-482
9. Wang Y., Belflower R.M., Dong Y.F., Schwarz E.M., O'Keefe R.J., and Drissi H. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J Bone Miner Res 20 (2005) 1624-1636
10. Hsu S.H., Noamani B., Abernethy D.E., Zhu H., Levi G., and Bendall A.J. Dlx5- and Dlx6-mediated chondrogenesis: differential domain requirements for a conserved function. Mech Dev 123 (2006) 819-830
11. Meech R., Edelman D.B., Jones F.S., and Makarenkova H.P. The homeobox transcription factor Barx2 regulates chondrogenesis during limb development. Development 132 (2005) 2135-2146
12. Robledo R.F., Rajan L., Li X., and Lufkin T. The Dlx5 and Dlx6 homeobox genes are essential for craniofacial, axial, and appendicular skeletal development. Genes Dev 16 (2002) 1089-1101
13. Seghatoleslami M.R., and Tuan R.S. Cell density dependent regulation of AP-1 activity is important for chondrogenic differentiation of C3H10T1/2 mesenchymal cells. J Cell Biochem 84 (2002) 237-248
14. Hwang S.G., Yu S.S., Lee S.W., and Chun J.S. Wnt-3a regulates chondrocyte differentiation via c-Jun/AP-1 pathway. FEBS Lett 579 (2005) 4837-4842
15. Lefebvre V., and Smits P. Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today 75 (2005) 200-212
16. Han Y., and Lefebvre V. L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 28 (2008) 4999-5013
17. Long F., Schipani E., Asahara H., Kronenberg H., and Montminy M. The CREB family of activators is required for endochondral bone development. Development 128 (2001) 541-550
18. Vale-Cruz D.S., Ma Q., Syme J., and LuValle P.A. Activating transcription factor-2 affects skeletal growth by modulating pRb gene expression. Mech Dev 125 (2008) 843-856
19. Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U., and Wagner E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 360 (1992) 741-745
20. Topol L., Chen W., Song H., Day T.F., and Yang Y. Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus. J Biol Chem 284 (2009) 3323-3333. In this study the authors used a biochemical approach to provided mechanistically inside how the nontranscriptional effect of Sox9 on beta-catenin levels, which had been reported previously by Akiyama et al. [59], is accomplished.
21. Yoshida C.A., and Komori T. Role of Runx proteins in chondrogenesis. Crit Rev Eukaryot Gene Expr 15 (2005) 243-254
22. •] suggests that there might be species differences in the Twist1 mediated regulation of chondrocyte hypertrophy.
23. Hinoi E., Bialek P., Chen Y.T., Rached M.T., Groner Y., Behringer R.R., Ornitz D.M., and Karsenty G. Runx2 inhibits chondrocyte proliferation and hypertrophy through its expression in the perichondrium. Genes Dev 20 (2006) 2937-2942. This in vivo study in the mouse has provided evidence that the interactions of Twist1 and Runx2 are not only involved in regulating osteoblastogenesis, but also important for chondrocyte hypertrophy. The results suggest that Runx2 in addition to promoting hypertrophy through its expression in chondrocytes, negatively regulates hypertrophy by acting in the perichondrium thereby providing an additional level of control in order to coordinate chondrocyte maturation and osteoblastogenesis.
24. Kempf H., Ionescu A., Udager A.M., and Lassar A.B. Prochondrogenic signals induce a competence for Runx2 to activate hypertrophic chondrocyte gene expression. Dev Dyn 236 (2007) 1954-1962
25. Wang W., Wang Y.G., Reginato A.M., Glotzer D.J., Fukai N., Plotkina S., Karsenty G., and Olsen B.R. Groucho homologue Grg5 interacts with the transcription factor Runx2-Cbfa1 and modulates its activity during postnatal growth in mice. Dev Biol 270 (2004) 364-381
26. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., McAnally J., Pomajzl C., Shelton J.M., Richardson J.A., et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119 (2004) 555-566. In this study it was shown for the first time by in vivo analysis of HDAC4 mutant mice that histone deacetylases, which can act as corepressors for transcription factors and are involved in chromatin structure regulation, play very specific roles in chondrogenesis.
27. Roca H., Phimphilai M., Gopalakrishnan R., Xiao G., and Franceschi R.T. Cooperative interactions between RUNX2 and homeodomain protein-binding sites are critical for the osteoblast-specific expression of the bone sialoprotein gene. J Biol Chem 280 (2005) 30845-30855
28. Chin H.J., Fisher M.C., Li Y., Ferrari D., Wang C.K., Lichtler A.C., Dealy C.N., and Kosher R.A. Studies on the role of Dlx5 in regulation of chondrocyte differentiation during endochondral ossification in the developing mouse limb. Dev Growth Differ 49 (2007) 515-521
29. Arnold M.A., Kim Y., Czubryt M.P., Phan D., McAnally J., Qi X., Shelton J.M., Richardson J.A., Bassel-Duby R., and Olson E.N. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 12 (2007) 377-389. In this in vivo study, the authors discovered that the transcription factor Mef2c also functions in regulating chondrocyte hypertrophy and that the activity of Mef2c in chondrocytes is fine-tuned by HDAC4. This study revealed an unexpected communality in the mechanism controlling hypertrophy in different cell types, including skeletal and heart muscle cells as well as chondrocytes.
30. Satokata I., Ma L., Ohshima H., Bei M., Woo I., Nishizawa K., Maeda T., Takano Y., Uchiyama M., Heaney S., et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 24 (2000) 391-395
31. Karreth F., Hoebertz A., Scheuch H., Eferl R., and Wagner E.F. The AP1 transcription factor Fra2 is required for efficient cartilage development. Development 131 (2004) 5717-5725
32. Amano K., Ichida F., Sugita A., Hata K., Wada M., Takigawa Y., Nakanishi M., Kogo M., Nishimura R., and Yoneda T. MSX2 stimulates chondrocyte maturation by controlling Ihh expression. J Biol Chem 283 (2008) 29513-29521
33. MacLean H.E., Kim J.I., Glimcher M.J., Wang J., Kronenberg H.M., and Glimcher L.H. Absence of transcription factor c-maf causes abnormal terminal differentiation of hypertrophic chondrocytes during endochondral bone development. Dev Biol 262 (2003) 51-63
34. Karsenty G. Minireview: transcriptional control of osteoblast differentiation. Endocrinology 142 (2001) 2731-2733
35. Bialek P., Kern B., Yang X., Schrock M., Sosic D., Hong N., Wu H., Yu K., Ornitz D.M., Olson E.N., et al. A twist code determines the onset of osteoblast differentiation. Dev Cell 6 (2004) 423-435. In this study, the authors could show using biochemical and in vivo studies that Twist proteins modulate Runx2 activity, providing a mechanistic explanation for the temporal discrepancy between Runx2 expression and the onset of its activity.
36. Jensen E.D., Schroeder T.M., Bailey J., Gopalakrishnan R., and Westendorf J.J. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 23 (2008) 361-372
37. Westendorf J.J. Transcriptional co-repressors of Runx2. J Cell Biochem 98 (2006) 54-64
38. Schmidt K., Schinke T., Haberland M., Priemel M., Schilling A.F., Mueldner C., Rueger J.M., Sock E., Wegner M., and Amling M. The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J Cell Biol 168 (2005) 899-910
39. Tribioli C., and Lufkin T. The murine Bapx1 homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. Development 126 (1999) 5699-5711
40. Holleville N., Mateos S., Bontoux M., Bollerot K., and Monsoro-Burq A.H. Dlx5 drives Runx2 expression and osteogenic differentiation in developing cranial suture mesenchyme. Dev Biol 304 (2007) 860-874
41. Lee M.H., Kim Y.J., Yoon W.J., Kim J.I., Kim B.G., Hwang Y.S., Wozney J.M., Chi X.Z., Bae S.C., Choi K.Y., et al. Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter. J Biol Chem 280 (2005) 35579-35587
42. Newberry E.P., Latifi T., and Towler D.A. Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. Biochemistry 37 (1998) 16360-16368
43. Shirakabe K., Terasawa K., Miyama K., Shibuya H., and Nishida E. Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. Genes Cells 6 (2001) 851-856
44. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., and de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108 (2002) 17-29
45. Matsubara T., Kida K., Yamaguchi A., Hata K., Ichida F., Meguro H., Aburatani H., Nishimura R., and Yoneda T. BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem 283 (2008) 29119-29125
46. Koga T., Matsui Y., Asagiri M., Kodama T., de Crombrugghe B., Nakashima K., and Takayanagi H. NFAT and Osterix cooperatively regulate bone formation. Nat Med 11 (2005) 880-885. This study showed in vivo that inhibition of NFATs using the drug FK506, which inhibits the phosphatase calcineurin an activator of NFAT, leads to reduced bone formation. These data were corroborated by in vitro studies showing that NFATc1 and NFATc2 deficient cells cannot form bone. In vitro binding studies showed that NFATc1 and Osterix interact on the protein level and that this interaction stimulates the transcriptional activity of Osterix thereby providing a potential mechanism of action.
47. Choo M.K., Yeo H., and Zayzafoon M. NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation. Bone 45 (2009) 579-589. This study together with a previous study from this group Yeo et al. [60] suggests a more complex role for NFATc1 in osteoblastogenesis. Using either high doses of the calcineurin inhibitor cyclosporin A in vivo Yeo et al. [60] or a constitutively form of NFATc1 in vitro this group provided evidence that NFAT might act as a negative regulator of osteoblast differentiation. While a low dose of the inhibitor stimulates bone formation.
48. Liu W., Toyosawa S., Furuichi T., Kanatani N., Yoshida C., Liu Y., Himeno M., Narai S., Yamaguchi A., and Komori T. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 155 (2001) 157-166
49. Maruyama Z., Yoshida C.A., Furuichi T., Amizuka N., Ito M., Fukuyama R., Miyazaki T., Kitaura H., Nakamura K., Fujita T., et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn 236 (2007) 1876-1890. In this study the authors used a transgenic mouse model expressing dominant-negative form of the transcription factor Runx2 in differentiated osteoblasts and showed that Runx2 activity is not essential to maintain the expression of major bone matrix protein genes in mature osteoblasts, hence raising the question about the in vivo relevance of previous findings that Runx2 is the major regulator of the expression of these bone matrix protein genes in vitro.
50. Xiao G., Jiang D., Ge C., Zhao Z., Lai Y., Boules H., Phimphilai M., Yang X., Karsenty G., and Franceschi R.T. Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem 280 (2005) 30689-30696
51. Dobreva G., Chahrour M., Dautzenberg M., Chirivella L., Kanzler B., Farinas I., Karsenty G., and Grosschedl R. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell 125 (2006) 971-986
52. Hassan M.Q., Javed A., Morasso M.I., Karlin J., Montecino M., van Wijnen A.J., Stein G.S., Stein J.L., and Lian J.B. Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol Cell Biol 24 (2004) 9248-9261
53. Gollner H., Dani C., Phillips B., Philipsen S., and Suske G. Impaired ossification in mice lacking the transcription factor Sp3. Mech Dev 106 (2001) 77-83
54. Yang X., and Karsenty G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J Biol Chem 279 (2004) 47109-47114
55. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., Li L., Brancorsini S., Sassone-Corsi P., Townes T.M., et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell 117 (2004) 387-398
56. Yu V.W., Akhouayri O., and St-Arnaud R. FIAT is co-expressed with its dimerization target ATF4 in early osteoblasts, but not in osteocytes. Gene Expr Patterns 9 (2009) 335-340
57. Eferl R., Hoebertz A., Schilling A.F., Rath M., Karreth F., Kenner L., Amling M., and Wagner E.F. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 23 (2004) 2789-2799
58. Provot S., Kempf H., Murtaugh L.C., Chung U.I., Kim D.W., Chyung J., Kronenberg H.M., and Lassar A.B. Nkx3.2/Bapx1 acts as a negative regulator of chondrocyte maturation. Development 133 (2006) 551-662
59. Akiyama H., Lyons J.P., Mori-Akiyama Y., Yang X., Zhang R., Zhang Z., Deng J.M., Taketo M.M., Nakamura T., Behringer R.R., McCrea P.D., and de Crombrugghe B. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev 18 (2003) 1072-1087
60. Yeo H., Beck L.H., McDonald J.M., and Zayzafoon M. Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone 40 (2007) 1502-1516